Autophagy inhibitor sensitizes MCF-7 breast cancer cells to novel cyclic tetrapeptide CTS203-induced caspase-9-dependent apoptotic cell death

Neoplasma

Volumn 62, Issue 2, 2015, Pages 220-229

  Wang, S ^a   Li, X ^a   Wang, Q ^a   Xiu, Z ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Autophagy; Beclin 1 cleavage; Cyclic tetrapeptide; HDAC inhibitor

Indexed keywords

BECLIN 1; CASPASE 9; HISTONE DEACETYLASE; HYDROXAMIC ACID DERIVATIVE; TETRAPEPTIDE; TETRAPEPTIDE CTS203; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 84930511694     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_027     Document Type: Article

References (33)

1. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3: 344–351. http://dx.doi.org/10.1016/S1471-4892(03)00084-5
2. PEART MJ, SMYTH GK, VAN LAARR K, BOWTELL DD, RICHON VM et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. PNAS 2005; 102: 3697–3702. http://dx.doi.org/10.1073/pnas.0500369102
3. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhbitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151–163.
4. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29: 255–265. http://dx.doi.org/10.1038/nbt.1759
5. SHIMIZE S, KANASEKE T, MIZUSHIMA N, MIZUTA T, Arakawa-Kobayashi S et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6: 1221–1228. http://dx.doi.org/10.1038/ncb1192
6. MILLS KR, REGINATO M, DEBNATH J, QUEENAN B, BRUGGEJ S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. PNAS 2004; 101: 3438–3443. http://dx.doi.org/10.1073/pnas.0400443101
7. ESKELINEN EL. The dual role of autophagy in cancer. Curr Opin Pharmacol 2011; 11: 294–300. http://dx.doi.org/10.1016/j.coph.2011.03.009
8. SUN W, CHEN J, WANG Y, ZHENG H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011; 7: 1035–1044. http://dx.doi.org/10.4161/auto.7.9.16521
9. CHEN S, KEHMAN SK, ZHANG W, WEN A, YAO L et al. Autophagy is therapeutic target in anticancer drug resistance. BBA-Rev Cancer 2010; 1806: 220–229.
10. PONTIKI E, Hadjipavlou-Litina D. Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSARperspectives. Med Res Rev 2012; 32: 1–165. http://dx.doi.org/10.1002/med.20200
11. WANG S, LI X, WEI Y, XIU Z, NISHINO N. Discovery of potent HDAC inhibitors based on Chlamydocin with inhibitory effects on cell migration. ChemMedChem 2014; 9: 627–637. http://dx.doi.org/10.1002/cmdc.201300372
12. SIEGEL R, NAISHADHAM D, JEMAL A. Cancer Statistics, 2013. CA Cancer J Clin 2013; 63: 11–30. http://dx.doi.org/10.3322/caac.21166
13. GUARNERI V, FRASSOLDATI A, GIOVANNELLI S, BORGHI F, CONTEP. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. Cancer Lett 2007; 248: 175–185. http://dx.doi.org/10.1016/j.canlet.2006.07.001
14. BRADBURY CA, KHANIM FL, HAYDEN R, BUNCEC M, WHITED A et al. Histone deacetylases in acute myeloid leukemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005; 9: 1751–1759. http://dx.doi.org/10.1038/sj.leu.2403910
15. GARRIDO C, GALLUZZI L, BRUNET M, PUIG PE, DIDELOT C et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006; 13: 1423–1433. http://dx.doi.org/10.1038/sj.cdd.4401950
16. VANDENABEELE P, BERGHE TV, FESTJENS N. Caspase inhibitors promote alternative cell death pathways. Sci. STKE 2006; 358: pe44.
17. MURI EMF, NIETO MJ, Sindelar RD, Williamson JS. Hydroxamic acids as pharmacological agents. Curr Med Chem 2002; 9: 1631–1653. http://dx.doi.org/10.2174/0929867023369402
18. XI G, HU X, WU B, JIANG H, YOUNG CTF, PANG Y et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer lett 2011; 307: 141–148. http://dx.doi.org/10.1016/j.canlet.2011.03.026
19. HEG, WANG Y, PANG X, ZHANG B. Inhibition of autophagy induced by TSA sensitizes colon cell to radiation. Tumor Biol 2014; 35: 1003–1011. http://dx.doi.org/10.1007/s13277-013-1134-z
20. KABEYA Y, MIZUSHIMA N, UENO T, YAMAMOTO A, KIRISAKO T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720–5728. http://dx.doi.org/10.1093/emboj/19.21.5720
21. CAO Q, YU C, XUE R, HSUEH W, PAN P et al. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int J Biochem Cell B 2008; 40: 272–283. http://dx.doi.org/10.1016/j.biocel.2007.07.020
22. YUE Z, JIN S, YANG C, LEVINEA J, HEINTZ N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. PNAS 2003; 100: 15077–15082. http://dx.doi.org/10.1073/pnas.2436255100
23. VIRAWAN E, WALLE LV, KERSSE K, CORNELIS S, CLAERHOUT S et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010; doi:10.1038/cddis.2009.16. http://dx.doi.org/10.1038/cddis.2009.16
24. CHO DH, JO YK, HWANG JJ, LEE YM, ROH SA et al. Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in Hela cells. Cancer Lett 2009; 274: 95–100. http://dx.doi.org/10.1016/j.canlet.2008.09.004
25. LIU T, KULJACA S, TEE A, MARSHALL GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006; 32: 157–165. http://dx.doi.org/10.1016/j.ctrv.2005.12.006
26. HUANG SW, LIU KT, CHANG CC, CHEN YJ, WU CY et al. Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Brit J Dermatol 2010; 163: 310–320. http://dx.doi.org/10.1111/j.1365-2133.2010.09827.x
27. Depere-Richer D, Kinal M, Menasche V, Nielsen TH, Rincon SD et al. Vorinostat-induced autophagy switches from a death-promoting to cytoprotective signal to drive acquired resistance. Cell Death Dis. 2013; doi:10.1038/cddis.2012.210. http://dx.doi.org/10.1038/cddis.2012.210
28. HOU W, HAN J, LU C, GOLDSTEIN LA, RABINOWICH H. Autophagic degradation of active caspase-8. Autophagy, 2010; 6: 891–900. http://dx.doi.org/10.4161/auto.6.7.13038
29. Abedin MJ, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007; 14: 500–510. http://dx.doi.org/10.1038/sj.cdd.4402039
30. ZHU Y, ZHAO L, LIU L, GAO P, TIAN W et al. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell 2010; 1: 468–477. http://dx.doi.org/10.1007/s13238-010-0048-4
31. GILLENWATER AM, ZHONG M, LOTAN R. Hitone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (CD95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007; 6: 2967–2975. http://dx.doi.org/10.1158/1535-7163.MCT-04-0344
32. CAREW JS, GILES FJ, NAWROCKI ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7–17. http://dx.doi.org/10.1016/j.canlet.2008.03.037
33. XIE C, EDWARDS H, XU X, ZHOU H, BUCK SA et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010; 16: 5499–5510. http://dx.doi.org/10.1158/1078-0432.CCR-10-1707